Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 70 years, who are male or not currently pregnant
• People whose cancer has been confirmed by a tissue biopsy as a specific type of nasopharyngeal (back-of-the-nose/throat) cancer classified as WHO Type II or III
• People whose cancer is classified as Stage IVB (an advanced stage with spread to distant parts of the body) according to standard cancer staging guidelines
• People who either have newly diagnosed nasopharyngeal cancer that has spread to the liver, or whose cancer spread to the liver more than 6 months after completing previous curative treatment (such as radiation therapy alone or combined with chemotherapy)
• People with a good general level of daily functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities)
• People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines
• People whose blood counts are within acceptable ranges — including white blood cells, platelets, and red blood cells (haemoglobin)
• People whose blood clotting test results are within acceptable limits
• People whose kidneys are functioning well enough, as shown by blood test results
• People whose liver function blood test results are within acceptable limits (a slightly higher level may be accepted for people with a specific inherited condition called Gilbert's syndrome)

Who may not be able to join:

• People whose cancer has come back at the original tumour site after they previously received full-course radiation therapy
• People whose tumour is growing into major blood vessels, which doctors assess as carrying a high risk of serious bleeding
• People who have received any systemic cancer treatment (including hormone therapy) within the 28 days before starting the trial
• People who have previously been treated with a type of cancer immunotherapy called immune checkpoint inhibitors (such as PD-1, PD-L1, or CTLA-4 inhibitors)
• People who have an active autoimmune disease, or a history of an autoimmune disease that could come back
• People with a known history of another cancer, unless it was a type of skin cancer (basal cell carcinoma) or cervical carcinoma in situ that has been fully cured
• People who have needed to take steroid medication (above a low daily dose equivalent) or other immune-suppressing medicines in the 14 days before treatment
• People with diabetes that is not well controlled, or who have significant abnormalities in their potassium, sodium, or calcium levels, or severely low protein (albumin) levels in the blood, within the 14 days before treatment
• People with a history of certain lung conditions, including scarring of the lung tissue (pulmonary fibrosis), inflammation of the lung not caused by infection, or acute lung disease
• People who have needed systemic antibiotics, antifungal, or antiviral medicines for a serious active infection (including tuberculosis) within the 14 days before the first dose
• People with a known history of HIV infection
• People with untreated chronic hepatitis B, or hepatitis B carriers with a viral level above a certain threshold, or people with active hepatitis C infection
• People who have had major surgery requiring general anaesthesia within the 28 days before treatment
• People who have previously had a stem cell transplant from a donor, or an organ transplant
• People with certain heart or blood vessel conditions, including recent cardiac chest pain limiting daily activities, a blood clot in the lung within the past 3 months, a heart attack within the past 6 months, significant heart failure within the past 6 months, certain heart rhythm problems within the past 6 months, or a stroke within the past 6 months
• People who have had significant or ongoing bleeding (such as from the stomach or gut, or persistent unexplained bleeding) in the 28 days before joining the trial
• People with a known allergy to any ingredient of the study drug, or a history of severe allergic reactions to similar medicines (monoclonal antibodies)
• People with moderate or severe nerve damage in their hands or feet (peripheral neuropathy rated Grade 2 or higher)
• People who have received a live vaccine within the 4 weeks before starting treatment
• People who are pregnant or currently breastfeeding
• People with other serious medical conditions, significant abnormal lab results, or personal or social circumstances that doctors consider could put them at risk or affect how the study is carried out
• People with alcohol or drug use issues that could affect how the treatment works or how results are recorded

Important: Always verify eligibility with the trial site directly before applying.